Search Results - "Chang, Alex H."

Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial by Xia, Jieyun, Li, Hujun, Yan, Zhiling, Zhou, Dian, Wang, Ying, Qi, Yuekun, Cao, Jiang, Li, Depeng, Cheng, Hai, Sang, Wei, Zhu, Feng, Sun, Haiying, Chen, Wei, Qi, Kunming, Yan, Dongmei, Qiu, Tingting, Qiao, Jianlin, Yao, Ruosi, Liu, Yang, Wang, Xue, Zhang, Yanlei, Peng, Shuixiu, Huang, Chih-Hua, Zheng, Junnian, Li, Zhenyu, Chang, Alex H, Xu, Kailin

“…G protein-coupled receptor, class C group 5 member D (GPRC5D) is considered to be a promising surface target for multiple myeloma (MM) immunotherapy. Here, we…”
Get full text

CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies by Hu, Yongxian, Li, Jingjing, Ni, Fang, Yang, Zhongli, Gui, Xiaohua, Bao, Zhiwei, Zhao, Houli, Wei, Guoqing, Wang, Yiyun, Zhang, Mingming, Hong, Ruimin, Wang, Linqin, Wu, Wenjun, Mohty, Mohamad, Nagler, Arnon, Chang, Alex H., van den Brink, Marcel R. M., Li, Ming D., Huang, He

“…Immunotherapy utilizing chimeric antigen receptor T cell (CAR-T) therapy holds promise for hematologic malignancies, however, response rates and associated…”
Get full text

Author Correction: T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection by Stephan, Matthias. T, Ponomarev, Vladimir, Brentjens, Renier .J, Chang, Alex. H, Dobrenkov, Konstantin. V, Heller, Glenn, Sadelain, Michel

Get full text

Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies by Zhang, Yinqiang, Li, Chenggong, Du, Mengyi, Jiang, Huiwen, Luo, Wenjing, Tang, Lu, Kang, Yun, Xu, Jia, Wu, Zhuolin, Wang, Xindi, Huang, Zhongpei, Zhang, Yanlei, Wu, Di, Chang, Alex H., Hu, Yu, Mei, Heng

“…Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is also…”
Get full text

Derivation and validation of a novel score for early prediction of severe CRS after CAR‐T therapy in haematological malignancy patients: A multi‐centre study by Zhou, Linghui, Fu, Weijun, Wu, Shenghao, Xu, Kailin, Qiu, Lugui, Xu, Yang, Yan, Xiaojing, Zhang, Qing, Zhang, Mingming, Wang, Linqin, Hong, Ruimin, Chang, Alex H., Yu, Jian, Fu, Shan, Kong, Delin, Li, Lu, Wang, Ying, Li, Zhenyu, Jiang, Huawei, Huang, Jing, Liu, Zhi, Su, Na, Wei, Guoqing, Hu, Yongxian, Huang, He

“…Summary Chimeric antigen receptor T (CAR‐T) cell therapy is highly effective in inducing complete remission in haematological malignancies. Severe cytokine…”
Get full text

Incidence, clinical characteristics and prognosis of tumor lysis syndrome following B-cell maturation antigen-targeted chimeric antigen receptor-T cell therapy in relapsed/refractory multiple myeloma by Zhang, Qiqi, Zu, Cheng, Jing, Ruirui, Feng, Youqin, Zhang, Yanlei, Zhang, Mingming, Lv, Yuqi, Cui, Jiazhen, Zhou, Linhui, Meng, Ye, Wang, Linqin, Cen, Zenan, Chang, Alex H, Hu, Yongxian, Huang, He

“…B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor-T cell (CAR-T) therapy is used for refractory or relapsed multiple myeloma (r/r MM)…”
Get full text

Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia by Tan, Yue, Shan, Lingling, Zhao, Liping, Deng, Biping, Ling, Zhuojun, Zhang, Yanlei, Peng, Shuixiu, Xu, Jinlong, Duan, Jiajia, Wang, Zelin, Yu, Xinjian, Zheng, Qinlong, Xu, Xiuwen, Tian, Zhenglong, Zhang, Yibing, Zhang, Jiecheng, Chang, Alex H, Feng, Xiaoming, Pan, Jing

“…Donor-derived CD7-directed chimeric antigen receptor (CAR) T cells showed feasibility and early efficacy in patients with refractory or relapsed T-cell acute…”
Get full text

New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia by Wang, Linqin, Hong, Ruimin, Zhou, Linghui, Ni, Fang, Zhang, Mingming, Zhao, Houli, Wu, Wenjun, Wang, Yiyun, Ding, Shuyi, Chang, Alex H., Hu, Yongxian, Huang, He

“…Although chimeric antigen receptor T (CAR-T) cell therapy has proven to be effective in treating relapsed or refractory B-cell hematological malignancies,…”
Get full text

Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study by Zhao, Houli, Wei, Jieping, Wei, Guoqing, Luo, Yi, Shi, Jimin, Cui, Qu, Zhao, Mingfeng, Liang, Aibin, Zhang, Qing, Yang, Jianmin, Li, Xin, Chen, Jing, Song, Xianmin, Jing, Hongmei, Li, Yuhua, Hao, Siguo, Wu, Wenjun, Tan, Yamin, Yu, Jian, Zhao, Yanmin, Lai, Xiaoyu, Yin, Elaine Tan Su, Wei, Yunxiong, Li, Ping, Huang, Jing, Wang, Tao, Blaise, Didier, Xiao, Lei, Chang, Alex H, Nagler, Arnon, Mohty, Mohamad, Huang, He, Hu, Yongxian

“…Consolidative allogeneic hematopoietic stem cell transplantation is a controversial option for patients with relapsed/refractory acute lymphoblastic leukemia…”
Get full text

Author Correction: CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies by Hu, Yongxian, Li, Jingjing, Ni, Fang, Yang, Zhongli, Gui, Xiaohua, Bao, Zhiwei, Zhao, Houli, Wei, Guoqing, Wang, Yiyun, Zhang, Mingming, Hong, Ruimin, Wang, Linqin, Wu, Wenjun, Mohty, Mohamad, Nagler, Arnon, Chang, Alex H., van den Brink, Marcel R. M., Li, Ming D., Huang, He

Get full text

Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission by Miao, Xiaojuan, Shuai, Yanrong, Han, Ying, Zhang, Nan, Liu, Yilan, Yao, Hao, Wang, Xiao, He, Guangcui, Chen, Dan, Fan, Fangyi, Chang, Alex H, Su, Yi, Yi, Hai

“…Explore the efficacy and safety of donor-derived CLL-1 chimeric antigen receptor T-cell therapy (CAR-T) for relapsed/refractory acute myeloid leukemia (R/R…”
Get full text

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy by An, Lihong, Lin, Yuehui, Deng, Biping, Yin, Zhichao, Zhao, Defeng, Ling, Zhuojun, Wu, Tong, Zhao, Yongqiang, Chang, Alex H, Tong, Chunrong, Liu, Shuangyou

“…For CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) after treatment with murine CD19 (mCD19) CAR-T, the reinfusion of mCD19…”
Get full text

Overexpression of CXCR7 accelerates tumor growth and metastasis of lung cancer cells by Liu, Huan, Cheng, Qian, Xu, Dong-sheng, Wang, Wen, Fang, Zheng, Xue, Dong-dong, Zheng, Ya, Chang, Alex H, Lei, Yan-jun

“…Abstract Background Under physiological conditions, CXCL12 modulates cell proliferation, survival, angiogenesis, and migration mainly through CXCR4…”
Get full text

HLA Fully-Mismatched Sibling-Derived CD7 CAR-T Therapy Bridging to Haploidentical Hematopoietic Stem Cell Transplantation for Hepatosplenic γδ T-cell Lymphoma by Xu, Xueer, Zu, Cheng, Zhang, Mingming, Xiao, Pingnan, Hong, Ruimin, Feng, Jingjing, Xu, Huijun, Cui, Jiazhen, Yu, Jian, Shi, Jimin, Wei, Guoqing, Chang, Alex H., Huang, He, Hu, Yongxian

“…While chimeric antigen receptor (CAR)-T-cell therapy has demonstrated remarkable effectiveness in the treatment of B-cell lymphomas and leukemias, research on…”
Get full text

Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy by Deng, Jingjing, Lin, Yuehui, Zhao, Defeng, Tong, Chunrong, Chang, Alex H., Chen, Wenming, Gao, Wen

“…Chimeric antigen receptor (CAR)-T cell therapy provides an effective salvage treatment for relapsed/refractory multiple myeloma (RRMM) patients. End-stage RRMM…”
Get full text

Short-Interval Sequential CAR-T Cell Infusion May Enhance Prior CAR-T Cell Expansion to Augment Anti-Lymphoma Response in B-NHL by Meng, Yuan, Deng, Biping, Rong, Luan, Li, Chuo, Song, Weiliang, Ling, Zhuojun, Xu, Jinlong, Duan, Jiajia, Wang, Zelin, Chang, Alex H., Feng, Xiaoming, Xiong, Xiujuan, Chen, Xiaoli, Pan, Jing

“…Chimeric antigen receptor (CAR)-T cell therapy emerges as a new treatment for refractory or relapsed (r/r) B-cell non-Hodgkin lymphoma (B-NHL); however, the…”
Get full text

Efficacy and Safety of Chimeric Antigen Receptor T Cells in Acute Lymphoblastic Leukemia With Post-Transplant Relapse by Ding, Lijuan, Wang, Yiyun, Hong, Ruimin, Zhao, Houli, Zhou, Linghui, Wei, Guoqing, Wu, Wenjun, Xu, Huijun, Zhang, Yanlei, Luo, Yi, Shi, Jimin, Chang, Alex H., Hu, Yongxian, Huang, He

“…Twenty patients with relapsed B-ALL after HSCT were treated with CAR T cell therapy and were evaluated for efficacy and safety. Twelve patients previously…”
Get full text

Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer by Li, Ning, Liu, Shaohui, Sun, Mingjiao, Chen, Wei, Xu, Xiaogang, Zeng, Zhu, Tang, Yemin, Dong, Yongquan, Chang, Alex H., Zhao, Qiong

“…Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) is overexpressed in more than 90% of non-small cell lung cancer (NSCLC) but not significantly in…”
Get full text

Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed/refractory B-ALL by Song, Fengmei, Hu, Yongxian, Zhang, Yanlei, Zhang, Mingming, Yang, Tingting, Wu, Wenjun, Huang, Simao, Xu, Huijun, Chang, Alex H, Huang, He, Wei, Guoqing

“…BackgroundMurine chimeric antigen receptor T (CAR-T) cell therapy has demonstrated clinical benefit in patients with relapsed/refractory (R/R) B-cell acute…”
Get full text

Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies by Wang, Linqin, Lv, Yuqi, Zhou, Linghui, Wu, Shenghao, Zhu, Yuanyuan, Fu, Shan, Ding, Shuyi, Hong, Ruimin, Zhang, Mingming, Yu, Hanjing, Chang, Alex H, Wei, Guoqing, Hu, Yongxian, Huang, He

“…Although the efficacy of chimeric antigen receptor (CAR)-T cell therapy has been widely demonstrated, its clinical application is hampered by the complexity…”
Get full text